Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET

Long-term multiple myeloma therapy by immunomodulatory drugs (IMiDs) raises the question of management of adverse effects. The aim of this study is to assess the impact of an educational session for patients on the acquisition of knowledge to manage hematologic and thromboembolic adverse effects of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2020-12, Vol.15 (12), p.e0243309
Hauptverfasser: Périchou, Juliette, Ranchon, Florence, Herledan, Chloé, Huot, Laure, Larbre, Virginie, Carpentier, Isabelle, Lazareth, Anne, Karlin, Lionel, Beny, Karen, Vantard, Nicolas, Schwiertz, Vérane, Caffin, Anne Gaelle, Baudouin, Amandine, Sesques, Pierre, Brisou, Gabriel, Ghesquières, Hervé, Salles, Gilles, Rioufol, Catherine
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Long-term multiple myeloma therapy by immunomodulatory drugs (IMiDs) raises the question of management of adverse effects. The aim of this study is to assess the impact of an educational session for patients on the acquisition of knowledge to manage hematologic and thromboembolic adverse effects of IMiDs. In this prospective single-center study, patients attended an educational session with a hospital clinical pharmacist and a nurse. The primary endpoint was the patient's level of knowledge for the management of IMiDs adverse effects, assess with a dedicated questionnaire administered before the session then 1 and 6 months after. Assessment of knowledge was combined with self-assessment of certainty. The secondary endpoints were adherence and IMiD treatment satisfaction. 50 patients were included. Patient knowledge increased at 1 month (p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0243309